
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Pusan, South Korea -- Intralesional interferon alfa-2b (Intron-A) can be a useful option for the treatment of rapidly growing keratoacanthomas, Chang-Keun Oh, M.D., Ph.D., said.






